The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].Howev...The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].However,it is clear nowadays that alterations other than Aβand tau deposition,e.g.,blood-brain-barrier(BBB)impairment[2]and impaired protein clearance[3],may take place in early disease stages,before consistent neu-rodegeneration occurs.Therefore,additional CSF bio-markers are needed.展开更多
Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be u...Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014.展开更多
基金MO,LP,PN SM and NGSJ are supported by the Marie Skłodowska-Curie grant agreement No.860197—MIRIADE project(European Union’s Horizon 2020 research and innovation program)GB is supported by the Postdoctoral Fellowship for Basic Scientists grant of the Parkinson’s Foundation(Award ID:PF-PRF-934916)+2 种基金LP and LG are funded by the European Union—Next Generation EU—PNRR M6C2—Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN(PNRR-MAD-2022–12376035)LB is supported by the Medical Faculty of Martin-Luther University Halle Wittenberg(Junior Clinician Scientist Programm No.JCS24/02)SAB received research support from the Medical Faculty of Martin-Luther University Halle-Wittenberg(Clinician Scientist-Programm No.CS22/06).
文摘The diagnosis of Alzheimer’s disease(AD)relies on the clinical evaluation of patients,often complemented by the analysis of core cerebrospinal fluid(CSF)biomark-ers(Aβ42/40,phosphorylated-Tau and total-tau)[1].However,it is clear nowadays that alterations other than Aβand tau deposition,e.g.,blood-brain-barrier(BBB)impairment[2]and impaired protein clearance[3],may take place in early disease stages,before consistent neu-rodegeneration occurs.Therefore,additional CSF bio-markers are needed.
基金Open Access funding enabled and organized by Projekt DEAL。
文摘Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014.
